A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
A second Lilly Nectin-4 ADC features among the latest phase 1 initiations.